To determine drug effectiveness and safety of the tumor necrosis factor (TNF)-alpha blocker monoclonal antibody adalimumab in a real-life cohort of 54 children and/or adolescents with severe plaque psoriasis.
Adalimumab in severe plaque psoriasis of childhood: a multi-center, retrospective real-life study up to 52 weeks observation
Stingeni, LConceptualization
;Hansel, KConceptualization
;
2019
Abstract
To determine drug effectiveness and safety of the tumor necrosis factor (TNF)-alpha blocker monoclonal antibody adalimumab in a real-life cohort of 54 children and/or adolescents with severe plaque psoriasis.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
